IDEXX Laboratories Announces First Quart...(Three Months Ended ...),Health

Date:4/24/2009

Three Months Ended March 31, March 31, 2009 2008 Key Operating Gross profit 52.6% 52.1% Ratios (as a Sales, marketing, percentage general and of revenue): administrative expense 29.6% 29.6% Research and development expense 6.7% 6.9% Income from operations (1) 16.3% 15.5% International International revenue Revenue: (in thousands) $90,412 $103,328 International revenue as a percentage of total revenue 38.2% 41.5% (1) The sum of individual items may not equal the total due to rounding. IDEXX Laboratories, Inc. and Subsidiaries Non-GAAP Financial Measures Amounts in thousands except per share data (Unaudited) Three Months Ended Income from Gross Profit Operations March 31, March 31, March 31, March 31, 2009 2008 2009 2008 GAAP measurement $124,433 $129,836 $38,441 $38,719 % of revenue 52.6% 52.1% 16.3% 15.5% Discrete income tax benefits (1) - - - - Non-GAAP comparative measurements (2) $124,433 $129,836 $38,441 $38,719 % of revenue 52.6% 52.1% 16.3% 15.5% Three Months Ended Earnings per Share Net Income D
'/>"/>

SOURCE IDEXX Laboratories, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
2. IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
3. IDEXX Laboratories Announces Fourth Quarter Results
4. IDEXX Laboratories Announces Increase in Share Repurchase Program
5. IDEXX Laboratories to Release 2008 First Quarter Financial Results
6. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
7. IDEXX Laboratories Names William Brown Corporate Vice President
8. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
9. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
10. IDEXX Laboratories to Release 2009 First Quarter Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)